Renal Denervation

Renal denervation (RDN) is a minimally invasive procedure performed by interventional cardiologists that treats uncontrolled hypertension by targeting overactive renal artery nerves with ablation. In 2025, CMS announced it was covering RDN in patients with uncontrolled hypertension. Decisions on whether or not to cover these procedures were previously made on a case-by-case basis.

Recor Medical's Paradise Ultrasound RDN system and Medtronic’s Symplicity Spyral RDN system both secured FDA approval in 2023. The early success of these devices resulted in the creation of new Category 1 CPT codes associated with improved reimbursement.

RSS icon
Paradise Ultrasound image courtesy of Recor Medical.

Both FDA-approved renal denervation systems linked to positive real-world outcomes

The real-world benefits of renal denervation were a hot topic at TCT 2026 in San Diego.

Renal denervation gains new Category I CPT codes

The establishment of dedicated CPT codes represents an important step in the broader reimbursement for renal denervation to treat uncontrolled hypertension.

Paradise Ultrasound image courtesy of Recor Medical.

Ultrasound RDN system launches in Japan—cardiologist calls it a ‘significant step forward’

Recor Medical's Paradise Ultrasound RDN technology is now available in Japan, home to an estimated 43 million adults with hypertension.

The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.

Medtronic’s RDN system receives new reimbursement approval

More than 40 million adults now have improved access to Medtronic's Symplicity Spyral renal denervation technology.

Herbert D. Aronow, MD, MPH, FACC, FSCAI, FSVM, medical director, heart and vascular service line and the Benson Ford Chair in Cardiology at Henry Ford Health, member of board, Society for Cardiovascular Angiography and Interventions (SCAI), the explains how hospitals can set up renal denervation (RDN) programs and how the reimbursement landscape is changing with new Medicare coverage.

How to get reimbursed for renal denervation

Herbert D. Aronow, MD, reviewed the many ways the reimbursement landscape is changing thanks to new Medicare policies. “This is a really exciting time in the renal denervation space," he said. 

Paradise Ultrasound image courtesy of Recor Medical.

More good news for renal denervation: FDA-approved systems linked to positive long-term data

New data on the RDN systems from Recor Medical and Medtronic confirmed that this relatively new technology brings long-term relief to patients with uncontrolled hypertension. 

Recor Medical's Paradise Ultrasound Renal Denervation System

Medicare now covers renal denervation for patients with uncontrolled hypertension

This decision expands access to renal denervation to many more patients throughout the United States. Recor Medical and Medtronic both gained FDA approval for their RDN systems in 2023, and other vendors are actively developing their own treatment options.

recor_paradise_system_-_sonication_dark_bg.png

Ultrasound renal denervation: A high-value treatment option for patients with uncontrolled hypertension

Sponsored by Recor Medical

Nearly 120 million adults in the United States have hypertension, and just 1 in 4 of them have it under control. Treatments remain limited outside of lifestyle changes and hypertensive medications that are not always effective.  

Displaying 1 - 8 of 26

Around the web

Radiology Business
Shielding system linked to lower operator radiation exposure during IR procedures
Health Exec
An inside look at the changing culture of the FDA